Description of Business and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Revenue Disaggregated by Segment, Product and Geography

The following table presents the Company’s revenue disaggregated by segment, product and geography (in thousands):

Biomedical market:

	Year Ended December 31, 2021
					Total		% of Total
	Domestic		International		Revenues		Revenues
Biomedical products
Cells	$	801	$	546	$	1,347		23	%
Media		3,935		654		4,589		77	%
Total	$	4,736	$	1,200	$	5,936		100	%

	Year Ended December 31, 2020
					Total		% of Total
	Domestic		International		Revenues		Revenues
Biomedical products
Cells	$	838	$	389	$	1,227		22	%
Media		3,903		447		4,350		78	%
Other		17		—		17		—
Total	$	4,758	$	836	$	5,594		100	%

Anti-aging market:

	Year Ended December 31,
	2021					2020
	Total		% of Total			Total		% of Total
	Revenues		Revenues			Revenues		Revenues
Skin care sales channels
Ecommerce	$	913		74	%	$	1,050		68	%
Professional		327		26	%		484		32	%
Total	$	1,240		100	%	$	1,534		100	%

Summary of Antidilutive Securities not Included in Diluted Net Loss Per Share Calculation

For the years ended December 31, 2021 and 2020, the following common stock options, common stock warrants and convertible preferred stock were not included in the diluted net loss per share calculation because the effect would be anti-dilutive.

	Years Ended December 31,
	2021		2020
Options outstanding		4,885,531		4,652,988
Common stock warrants outstanding		—		3,949,281
Redeemable convertible preferred stock		2,457,143		2,457,143
Non-redeemable convertible preferred stock		3,385,075		3,675,135
Total		10,727,749		14,734,547